LGC Seracare Seraseq Oncology Reference Controls
LGC Seracare has added four new products to its somatic cancer reference control portfolio. The Seraseq MSI Reference Panel Mix AF5% and AF20% are the company's first microsatellite instability reference materials that target the lengths of the regions commonly referred to as BAT-25, BAT-26, NR-21, NR-24, and MONO-27. These markers are blended at two different allele frequency levels (5 percent and 20 percent) to support MSI assay limit of detection determinations and accurate analysis of MSI status of patient samples.
The Seraseq NTRK Fusion RNA Mix is a 15-plex RNA mix of NTRK fusion genes that are important in next-generation sequencing assay evaluation of cancer patients harboring NTRK fusions for therapeutic intervention. This new product complements LGC Seracare's existing 15-plex FFPE NTRK reference material.
The Seraseq Compromised FFPE WT (DNA/RNA) RM is a more "patient-like (compromised)" negative sample control in FFPE format. A single FFPE section offers both RNA and DNA for targeted NGS assay validation and/or routine use in clinical testing. This product is complementary to the recently released Seraseq TNA WT (DNA/RNA) as well as mutation-positive Seraseq DNA and RNA reference materials, the company said.
All products are available in purified and FFPE formats, the company said.
Discovery Life Sciences SpecimenSeq
Discovery Life Sciences has launched SpecimenSeq, a collection of high-quality, fully consented biospecimens to help researchers identify, develop, and validate new biomarker signatures for precision medicine applications.
SpecimenSeq is composed of matched biospecimen sets including FFPE, double-spun plasma, and buffy coat formats from treatment-naive cancer patients. The biospecimens are fully annotated with clinical data and the FFPE biospecimens specifically include clinically relevant genomic variants from 64 genes. Genomic data for SpecimenSeq are produced using the custom HAD QGEN MultiModal Panel-based DNA and RNA analysis service available exclusively through Discovery's sequencing and bioinformatics laboratory, HudsonAlpha Discovery. This panel service uses Qiagen's QiaSeq MultiModal targeted DNA and RNA sequencing chemistry and analysis platform that is also available as a standalone service through HudsonAlpha Discovery with variant allele frequency detection at less than 5 percent.
Igenomix has launched Embrace, a non-invasive test for prioritizing embryo transfer. Embrace scores embryos according to their probability of being healthy and viable based on chromosomal information. Rather than removing cells from a developing embryo through biopsy, Embrace enables scientists at Igenomix to use next-generation sequencing to test the drop of the culture medium in which a six-day-old embryo, or blastocyst, has developed to count the chromosome number of the embryonic cell-free DNA. A score is then given to determine the probability of the embryo being healthy and viable, the company said. According to the company the test will enable embryonic chromosome analysis to be accessible to a larger number of in vitro fertilization centers and patients, as it simplifies the process and increases chances of IVF success. Igenomix said that it is offering Embrace to the 400 US fertility centers it currently works with.
For more new products and services, please visit the New Products page on our website.